CN110672567B - Low molecular weight heparin gold nano material and application thereof in heparanase detection - Google Patents
Low molecular weight heparin gold nano material and application thereof in heparanase detection Download PDFInfo
- Publication number
- CN110672567B CN110672567B CN201910916199.5A CN201910916199A CN110672567B CN 110672567 B CN110672567 B CN 110672567B CN 201910916199 A CN201910916199 A CN 201910916199A CN 110672567 B CN110672567 B CN 110672567B
- Authority
- CN
- China
- Prior art keywords
- gold
- molecular weight
- low molecular
- heparanase
- weight heparin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 title claims abstract description 78
- 239000010931 gold Substances 0.000 title claims abstract description 50
- 229910052737 gold Inorganic materials 0.000 title claims abstract description 50
- 239000003055 low molecular weight heparin Substances 0.000 title claims abstract description 48
- 229940127215 low-molecular weight heparin Drugs 0.000 title claims abstract description 47
- 102100024025 Heparanase Human genes 0.000 title claims abstract description 39
- 108010037536 heparanase Proteins 0.000 title claims abstract description 39
- 238000001514 detection method Methods 0.000 title claims abstract description 19
- 239000002086 nanomaterial Substances 0.000 title claims abstract description 15
- 239000002105 nanoparticle Substances 0.000 claims abstract description 31
- 230000000694 effects Effects 0.000 claims abstract description 26
- 239000000758 substrate Substances 0.000 claims abstract description 13
- 238000012546 transfer Methods 0.000 claims abstract description 10
- 230000008859 change Effects 0.000 claims abstract description 8
- 230000015556 catabolic process Effects 0.000 claims abstract description 4
- 238000006731 degradation reaction Methods 0.000 claims abstract description 4
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims description 13
- 230000009467 reduction Effects 0.000 claims description 9
- 238000006722 reduction reaction Methods 0.000 claims description 9
- 125000003277 amino group Chemical group 0.000 claims description 5
- 108010022901 Heparin Lyase Proteins 0.000 claims description 4
- 238000006845 Michael addition reaction Methods 0.000 claims description 3
- 238000006268 reductive amination reaction Methods 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 17
- 238000000034 method Methods 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 9
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 8
- 239000012154 double-distilled water Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000005284 excitation Effects 0.000 description 6
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(I) nitrate Inorganic materials [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 229960003180 glutathione Drugs 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 229910004042 HAuCl4 Inorganic materials 0.000 description 3
- 229920002971 Heparan sulfate Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- -1 benzethonium chloramide ester Chemical class 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical class [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 229910052681 coesite Inorganic materials 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 229910052906 cristobalite Inorganic materials 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 238000000695 excitation spectrum Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229910052682 stishovite Inorganic materials 0.000 description 2
- 229910052905 tridymite Inorganic materials 0.000 description 2
- YEDNBEGNKOANMB-REOHCLBHSA-N (2r)-2-amino-3-sulfanylpropanamide Chemical compound SC[C@H](N)C(N)=O YEDNBEGNKOANMB-REOHCLBHSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 229960003872 benzethonium Drugs 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- ANORDWOIBSUYBN-UHFFFAOYSA-N n-chloro-1-phenylmethanamine Chemical compound ClNCC1=CC=CC=C1 ANORDWOIBSUYBN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035040 seed growth Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940071240 tetrachloroaurate Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6432—Quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
本发明公开了一种低分子量肝素金纳米材料及其在乙酰肝素酶检测中的应用，通过采用金纳米颗粒和金纳米棒对直径小于10 nm的低分子量肝素进行共价双标记，利用荧光能量共振转移（FRET）的方式检测肝素酶降解后底物的FRET值变化来反映乙酰肝素酶活性值，从而有效避免二次裂解对乙酰肝素酶活性测定带来的影响。
The invention discloses a low-molecular-weight heparin gold nanomaterial and its application in the detection of heparanase. By using gold nanoparticles and gold nanorods to covalently double-label low-molecular-weight heparin with a diameter of less than 10 nm, fluorescence Energy resonance transfer (FRET) is used to detect the change of the FRET value of the substrate after heparanase degradation to reflect the heparanase activity value, thereby effectively avoiding the influence of secondary cleavage on the determination of heparanase activity.
Description
Technical Field
The invention belongs to the technical field of biomedicine, and particularly relates to gold nano-material double-labeled low-molecular-weight heparin and application thereof in heparanase detection.
Background
Heparan sulfate is a long-chain glycosaminoglycan composed of uronic acid and glucosamine alternately, widely exists in tumor Extracellular Matrix (ECM) and cell surface, is a main component of basement membrane, and can provide attachment points for growth factors, vascular endothelial growth factors, protein kinases and the like in vivo. Heparanase is the only endogenous hydrolase found in human body which can hydrolyze heparan sulfate so far, and the activity of the heparanase is closely related to tumor. Multiple studies show that the expression level of heparanase is obviously higher than the normal level in the later stage of tumor development, and the over-expressed heparanase can promote the growth of tumor cells, the generation of blood vessels, infiltration and migration, so that the survival rate of tumor patients is greatly reduced. Therefore, the activity detection of heparanase is an important link for judging the occurrence and development of tumors.
The activity detection is a key detection index in the research process of heparanase, and the time of enzyme catalytic reaction, the reaction dosage of enzyme and substrate and the like can be calculated by measuring the activity of the enzyme. Two methods are commonly used for the determination of heparanase activity: one is to detect the change of the content of the substrate or product before and after the catalytic reaction by means of HPLC and the like; the other is to detect structural changes of the substrate and product before and after catalysis by absorbance. Because of the complex structure of heparin substrate and the lack of characteristic absorption groups, neither of the above two methods can be used to establish a direct method for measuring heparanase activity.
Disclosure of Invention
The invention aims to overcome the defects of the prior art for heparanase activity detection, and provides gold nano-material double-labeled low-molecular-weight heparin and application thereof in heparanase detection. The gold nanoparticles and the gold nanorods are adopted to carry out covalent double labeling on the low molecular weight heparin with the diameter less than 10nm, and the FRET value change of the substrate after the degradation of the heparinase is detected by utilizing a fluorescence energy resonance transfer (FRET) mode to reflect the activity value of the heparanase, so that the influence of secondary cracking on the activity determination of the heparanase is effectively avoided.
In order to achieve the purpose, the invention adopts the following technical scheme:
a gold nano material of low molecular weight heparin is characterized in that gold nano particles are connected with the non-reduction end of the low molecular weight heparin, and gold nano rods are connected with the reduction end of the low molecular weight heparin.
Further, the low molecular weight heparin has a diameter of less than 10 nm.
Further, the gold nanoparticles are connected to the non-reducing end of the low molecular weight heparin in a Michael addition manner through sulfydryl, and the gold nanorods are combined to the reducing end of the low molecular weight heparin through an amino group in a reductive amination manner.
The application of the low molecular weight heparin gold nano material in heparanase activity detection.
The application of the low molecular weight heparin gold nano material in heparanase detection.
The invention adopts the characteristic of combining gold nano-material and polysaccharide, obtains the FRET probe substrate for the heparinase activity determination by carrying out covalent double labeling on the low molecular weight heparin with the diameter less than 10nm based on the fluorescence quenching effect characteristics of the gold nano-particles and the gold nano-rods with high quantum efficiency, and effectively utilizes the advantages of wide excitation spectrum, narrow emission spectrum, adjustable emission wavelength along with the size, long fluorescence life, high photochemical stability and the like of the gold nano-material. Compared with fluorescent micromolecules, the double-labeled low-molecular heparin is used for detecting the activity of heparanase, has higher sensitivity and low toxicity, and reduces the risk of clinical use. Meanwhile, the fluorescence has long service life and is not easy to bleach, and the sensitivity of enzyme activity detection is improved.
In addition, the technical means of carrying out covalent double labeling by adopting gold nanoparticles and gold nanorod energy transfer molecules can carry out specific covalent modification on other in-vivo proteins so as to realize positioning tracing on polysaccharide and quantitative analysis on protein.
Has the advantages that:
1. the activity of heparanase is detected by using low molecular weight heparin to replace expensive heparan sulfate, so that the cost of an experiment is reduced;
2. compared with HPLC detection of heparanase activity, the method is simple, convenient and quick, and saves a large amount of time; compared with the method using absorbance for detection, the method improves the detection sensitivity, can efficiently and quickly monitor the activity of heparanase, and can be used for screening other enzyme proteins at high flux.
Drawings
FIG. 1 is a schematic diagram of fluorescence resonance energy transfer of double-labeled low molecular weight heparin in the invention.
FIG. 2 is the excitation/emission spectrum of gold nanoparticles (AuNCs @ GSH-cys) and gold nanorods in example 1（AuNRs/side-SiO2/end-NH2) The absorption spectrum of (2).
FIG. 3 shows the activity of heparanase on the surface of different cells in example 2.
Detailed Description
The technical scheme of the invention is further explained by combining specific examples, and the experimental methods in the following examples are all conventional methods unless otherwise specified. The test materials used in the following examples were purchased from a conventional biochemical reagent store unless otherwise specified.
As shown in figure 1, based on the fluorescence quenching effect characteristics of the gold nanoparticles (A) and the gold nanorods (B) with high quantum efficiency, the method disclosed by the invention can be used for reflecting the activity value of heparanase by carrying out covalent double labeling on low-molecular-weight heparin with the diameter less than 10nm and detecting the change of FRET value of a substrate after the degradation of the heparanase in a fluorescence energy resonance transfer (FRET) mode, so that the influence of secondary cracking on the activity determination of the heparanase is effectively avoided.
The gold nanoparticles and the gold nanorods can be specifically and respectively covalently bonded to the non-reduction end and the reduction end of the low molecular weight heparin to prepare the low molecular weight heparin modified by the gold nanomaterial, thereby providing good support for researching the expression and activity detection of heparanase on the surface of tumor cells. Meanwhile, the gold nanoparticles or gold nanorods can also carry out specific covalent modification on other in-vivo proteins, and a novel monitoring strategy is provided for the research of the interaction between the proteins and the conformational change of the proteins.
Fluorescence Resonance Energy Transfer (FRET) refers to the phenomenon of energy transfer that occurs when two fluorescent molecules are close together (less than 10 nm), and is commonly used to detect the positional relationship of two different small molecules. The length of the low molecular weight heparin (LWMH) selected in the invention is less than 10nm, so that the gold nanoparticles marked at both ends of the LWMH and the gold nanorods can generate energy resonance transfer.
Example 1
Preparation of double-labeled Low molecular weight heparin
1. Preparation of gold nanoparticles (AuNCs @ GSH-cys)
78.7 mg of HAuCl was taken4·4H2O was dissolved in 20 mL of double distilled water, and the solution was sufficiently dissolved with stirring to prepare a 10 mM aqueous tetrachloroaurate solution. And (3.0) mL of the solution is taken, 4.15 mL of double distilled water and 2.85 mL of 10 mM reduced Glutathione (GSH) solution are added, the mixture is fully stirred, the temperature is set to be 90 ℃, the reaction is carried out for 50 min, and then AuNCs @ GSH solution is obtained, and a fluorescence spectrophotometer is used for measuring the optimal excitation wavelength and the optimal emission wavelength. In order to obtain the optimal fluorescence intensity, the molar ratio of glutathione to tetrachloroauric acid is groped to improve the fluorescence property of the gold nanoclusters. The molar ratio of the two is set in the experiment, [ GSH]/[HAuCl4]The molar ratio is 0.8:1-1.1: 1. After the reaction is finished, centrifuging at 12000 r/min to remove large particles, dialyzing overnight by using a dialysis membrane with the molecular weight of 500 Da, then re-suspending the gold nanoparticles by double distilled water, and storing at 4 ℃ in a dark place for later use.
In order to obtain gold nanoparticles with sulfydryl on the surface, the AuNCs @ GSH is subjected to cysteine amide condensation reaction. 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDC, carboxyl activating reagent) and N-hydroxysuccinimide (NHS, coupling agent), wherein the molar ratio of [ EDC ]/[ NHS ] is set to be 1: 2.5 in an experiment, the EDC is ensured to be added with the concentration which is about 10 times of the concentration of the gold nanoparticles, the equimolar cysteine is added, the gold nanoparticles are slowly mixed for 2 hours at room temperature, and after overnight dialysis is carried out by using a dialysis membrane with the molecular weight of 500 Da, double distilled water is used for re-suspending the gold nanoparticles, and the gold nanoparticles AuNCs @ GSH-cys are kept away from light at 4 ℃ for later use, so that the gold nanoparticles AuNCs @ GSH-cys are obtained.
2. Gold nanorods (AuNRs/side-SiO)2/end-NH2) Preparation of
The gold nanorods were prepared according to a seed growth method. The method comprises the following specific steps: to 0.25 mL 10 mM HAuCl4·4H29.5 mL of 10 mM cetyltrimethylammonium bromide (CTAB) solution was slowly dropped into the O aqueous solution, and after sufficiently stirring, 0.6 mL of 10 mM NaBH precooled was slowly dropped4And (3) mixing the solution uniformly, rapidly and violently stirring for 2 min, and standing for 2 h at room temperature to obtain the gold seed solution. Another 9.5 mL 10 mM CTAB solution was added with 0.5 mL 10 mM HAuCl4Solution, 140. mu.L 10 mM AgNO3Solution, 0.055 mL 0.1M ascorbic acid solution, stirring well. And slowly dripping 12 mu L of gold seed solution into the solution, stirring for 10 s, and standing for 24h to obtain a gold nanorod (AuNRs) solution. Can be adjusted according to AgNO3The added amount adjusts the maximum absorbance of the gold nanorods. Provided with AgNO3The amounts added were 80. mu.L, 100. mu.L, 120. mu.L, 140. mu.L, 180. mu.L, 210. mu.L, and 240. mu.L. After the reaction is finished, centrifuging at 10000 rpm for 15 min, removing unreacted and excessive reagents in the supernatant, repeating twice, and suspending into double distilled water for later use.
To obtain gold nanorods with amino groups on the surface, taking the AuNRs solution, adding 100 mu L of 10 mM cysteamine solution, stirring for 3 h at room temperature, centrifuging for 15 min at 10000 rpm after the reaction is finished, removing unreacted and excessive reagents in supernatant, repeating twice, and resuspending into double distilled water for later use to obtain the AuNRs-NH with aminated surface2And (3) solution.
Because the surface of low molecular weight heparin (LWMH) has negative charges, AuNRs-NH2The solution has positive charge, and in order to avoid charge interaction, the invention adopts silicification AuNRs-NH2The solution is made to have a negative charge on its surface. The method comprises the following specific steps: to 3 mL of AuNRs-NH2Adding TEOs solution (1.75 wt% dissolved in ethanol) 80 μ L and 0.1M NaOH solution 30 μ L sequentially, and stirring at room temperature for 10 hr to obtain AuNRs/side-SiO2/end-NH2 And (3) solution. The surface area of the gold nanorods subjected to silicification is adjusted by changing the addition amount of the TEOs solution, and finally, the gold nanorods are wrapped with silicon while two ends of the gold nanorods are exposed. The amounts of TEOs solution added were 60. mu.L, 80. mu.L, 100. mu.L, 120. mu.L, 140. mu.L for the experimental settings. After the reaction is finished, centrifuging at 10000 rpm for 15 min, removing unreacted and excessive reagents in the supernatant, repeating twice, and suspending into double distilled water for later use.
3. Preparation of double-labeled Low molecular weight heparin (LWMH)
The reactivity of terminal double bonds is increased by esterifying carboxyl groups on LWMH, then gold nanoparticles (A) having mercapto groups on the surface are site-specifically bonded to non-reducing terminals of LWMH by Michael addition reaction catalyzed by boric acid catalyst, and finally the protective ester is removed under alkaline conditions, thereby forming non-reducing terminal-labeled A-LWMH. On the basis, gold nanorods (B) with amino groups on the surface are marked on the reduction end of LWMH-M by using catalyst sodium borohydride to obtain FRET probe substrate A-LWMH-B for detecting heparinase activity.
(1) Preparation of LWMH benzethonium chloramide ester: dissolving 500 mg LWMH in 5 mL water (solution A), dissolving 1.25 g benzylchloramine in 15 mL water (solution B), slowly dropping solution B into solution A to produce a white solid, stirring at 1000 rpm for 1 h, standing for 1 h, removing supernatant, adding equal volume of water, stirring for 15 min, standing for 30 min, repeating once, filtering, and drying under reduced pressure at 30 ℃ for 20 h. After 0.59 g of LWMH benzethonium chloride salt was completely dissolved in 23.15 mL of dichloromethane, 4.915 mL of benzyl chloride was slowly added dropwise and stirred at 30 ℃ and 400 rpm for 24 hours to obtain 52 mg of LWMH benzethonium chloride ester.
(2) Preparation of A-LWMH: adding 45 mg of LWMH benzethonium chloride into 10 mL of formamide solution, heating at 50 ℃ until the mixture is completely dissolved, adding gold nanoparticle solid (58.8 mg, 0.3 mmol) with sulfydryl on the surface and boric acid (18.6 mg, 0.3 mmol) into the formamide solution, and reacting at 50 ℃ in a dark place for 24 hours. And after the reaction is finished, dialyzing for 48 hours in 50% ethanol by using a dialysis bag with the molecular weight cutoff of 500, removing unreacted gold nanoparticle molecules, and freeze-drying to obtain the gold nanoparticle-marked A-LWMH.
(3) Preparation of A-LWMH-B: 15 mg of A-LWMH marked by gold nanoparticles is dissolved in 560 mu L of distilled water, 4 mg of gold nanorods with amino groups on the surface are dissolved in 158 mu L of acetic acid/DMSO (3: 17) solution, after the two are mixed uniformly, 25 mg of sodium borohydride solution is added, and the reaction is carried out for 16 h at 37 ℃. After the reaction, 500. mu.L of DMSO was added to dissolve the precipitated precipitate, and the resulting solution was dialyzed for 24 hours using a dialysis bag having a molecular weight cut-off of 500 to remove unreacted substances, followed by lyophilization to obtain FRET substrate A-LWMH-B.
As shown in FIG. 2, the excitation wavelength and emission wavelength of gold nanoparticles (AuNCs @ GSH-cys) were scanned by a fluorescence spectrophotometer, and the optimal excitation wavelength (. lamda.ex) was 560 nm and the optimal emission wavelength was foundThe emission wavelength (lambda em) is 824 nm, and the gold nanorods (AuNRs/side-SiO) are measured by an ultraviolet spectrophotometer2/end-NH2) The optimal absorption peak is 825 nm, and the result shows that the emission wavelength of the gold nanoparticle (AuNCs @ GSH-cys) and the gold nanorod (AuNRs/side-SiO)2/end-NH2) The longitudinal surface plasma resonance absorption peak (LSPR peak) overlapping rate can reach more than 95 percent, so gold nano-rod (AuNRs/side-SiO) is selected2/end-NH2) As the acceptor group of gold nanoparticles (AuNCs @ GSH-cys), an energy resonance transfer molecule pair is formed.
Example 2
Application of A-LWMH-B in detection of heparanase on tumor cell surface
Preparing 1 mg/mL A-LWMH-B double-labeled fluorescent substrate by using DMEM, taking 100 uL of the substrate solution, adding 100 uL cultured for 24h respectively, wherein the cell density is 1 x 105Different tumor cells (cervical cancer cell Hela/breast cancer cell MCF-7/breast cancer cell MAB-MD-231/lung cancer cell A549) and normal cell 293t cell, 5% CO at 37 deg.C2The cells were incubated for 12 hours and the change in fluorescence under 560 nm excitation was recorded.
Because heparanase has high expression in various malignant tumors and is closely related to invasion and metastasis of malignant tumor cells, the expression and activity conditions of the heparanase on the surface of the tumor cells can be monitored by using the gold nanoparticle and gold nanorod double-modified low-molecular-weight heparin prepared by the invention, namely the metastasis condition result of the tumor cells is judged by monitoring the change condition of the fluorescence value at the excitation wavelength of the gold nanoparticle of 560 nm. After the double-modified low-molecular-weight heparin is mixed with tumor cells, heparanase on the surface of the double-modified low-molecular-weight heparin specifically degrades the double-modified low-molecular-weight heparin, as shown in fig. 3, compared with a normal cell group human renal epithelial cell line (293 t), FRET fluorescence values of cancer cell groups are increased to different degrees, for example, fluorescence value (RFU) in a breast cancer cell (MAB-MD-231) system is increased to 7824 compared with normal cells, further, the expression level of the heparanase on the surface of the breast cancer cell (MAB-MD-231) is the highest, the transfer capacity of the heparanase is stronger, and the cancer cell (Hela) is the next cervical cancer cell.
Claims (4)
1. A low molecular weight heparin gold nano-material is characterized in that: the non-reduction end of the low molecular weight heparin is connected with gold nanoparticles, and the reduction end of the low molecular weight heparin is connected with gold nanorods;
the diameter of the low molecular weight heparin is less than 10 nm;
the gold nanorods are used as acceptor groups of the gold nanoparticles to form an energy resonance transfer molecular pair, and the change of the FRET value of a substrate after heparinase degradation is detected by utilizing a fluorescence energy resonance transfer FRET mode to reflect the activity value of heparanase.
2. The low molecular weight heparin gold nanomaterial of claim 1, wherein: the gold nanoparticles are connected to the non-reduction end of the low molecular weight heparin in a Michael addition mode through sulfydryl, and the gold nanorods are combined to the reduction end of the low molecular weight heparin through an amino group in a reductive amination mode.
3. The use of the low molecular weight heparinized gold nanomaterial of claim 1 in heparanase detection.
4. The use of the low molecular weight heparinized gold nanomaterial of claim 1 in the detection of heparanase activity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910916199.5A CN110672567B (en) | 2019-09-26 | 2019-09-26 | Low molecular weight heparin gold nano material and application thereof in heparanase detection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910916199.5A CN110672567B (en) | 2019-09-26 | 2019-09-26 | Low molecular weight heparin gold nano material and application thereof in heparanase detection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110672567A CN110672567A (en) | 2020-01-10 |
| CN110672567B true CN110672567B (en) | 2022-01-11 |
Family
ID=69079207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910916199.5A Active CN110672567B (en) | 2019-09-26 | 2019-09-26 | Low molecular weight heparin gold nano material and application thereof in heparanase detection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110672567B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101208437A (en) * | 2003-12-12 | 2008-06-25 | 圣路易斯大学 | Biosensors for detection of macromolecules and other analytes |
| CN101491835A (en) * | 2009-02-27 | 2009-07-29 | 江南大学 | Preparation method of heparin modified gold nano-particles |
| CN102495038A (en) * | 2011-12-09 | 2012-06-13 | 南京大学 | Optical ion sensing film for detecting metal ions, and preparation method and application thereof |
| CN103743837A (en) * | 2013-12-24 | 2014-04-23 | 山东泰邦生物制品有限公司 | Human anti-thrombin III heparin combination ratio detection method |
| CN108489976A (en) * | 2018-03-21 | 2018-09-04 | 湖南科技大学 | A kind of preparation method of gold nanorods gold nanoclusters compound quick detection kit |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050042213A1 (en) * | 2003-08-14 | 2005-02-24 | Insight Biopharmaceuticals Ltd. | Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof |
-
2019
- 2019-09-26 CN CN201910916199.5A patent/CN110672567B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101208437A (en) * | 2003-12-12 | 2008-06-25 | 圣路易斯大学 | Biosensors for detection of macromolecules and other analytes |
| CN101491835A (en) * | 2009-02-27 | 2009-07-29 | 江南大学 | Preparation method of heparin modified gold nano-particles |
| CN102495038A (en) * | 2011-12-09 | 2012-06-13 | 南京大学 | Optical ion sensing film for detecting metal ions, and preparation method and application thereof |
| CN103743837A (en) * | 2013-12-24 | 2014-04-23 | 山东泰邦生物制品有限公司 | Human anti-thrombin III heparin combination ratio detection method |
| CN108489976A (en) * | 2018-03-21 | 2018-09-04 | 湖南科技大学 | A kind of preparation method of gold nanorods gold nanoclusters compound quick detection kit |
Non-Patent Citations (3)
| Title |
|---|
| Fluorometric determination of the activity of alkaline phosphatase based on the competitive binding of gold nanoparticles and pyrophosphate to CePO4:Tb nanorods;Ai-Zhen Xu等;《Microchimica Acta》;20180509;第185卷;第288-1至288-8页 * |
| Rapid detection of heparin by gold nanorods and near-infrared fluorophore ensemble based platform via nanometal surface energy transfer;Jia Jun Liu等;《Sensors & Actuators: B. Chemical》;20180730;第274卷;第318–323页 * |
| 低相对分子质量肝素联合多柔比星对肝癌细胞迁移能力的影响;杨克红 等;《J South Med Univ》;20141231;第34卷(第7期);第1048-1052页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110672567A (en) | 2020-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shao et al. | Electrochemical and spectroscopic studies on the conformational structure of hemoglobin assembled on gold nanoparticles | |
| Lin et al. | Acetaldehyde-modified-cystine functionalized Zr-MOFs for pH/GSH dual-responsive drug delivery and selective visualization of GSH in living cells | |
| CN102749317B (en) | Surface enhanced Raman scattering probe based on carbon nanotube and preparation method thereof | |
| CN103239738A (en) | Preparation method of pegylation modified hyperbranched poly(ethylene imine) coated nano-gold particles | |
| Qasemi et al. | Highly sensitive and strongly fluorescent gum tragacanth based superabsorbent hydrogel as a new biosensor for glucose optical detection | |
| Duan et al. | Chitosan-stabilized self-assembled fluorescent gold nanoclusters for cell imaging and biodistribution in vivo | |
| CN103920889A (en) | Application of thiol-polyethylene glycol in preparation of water-soluble gold nano-clusters | |
| CN102861344A (en) | Preparation of gold nanoparticle coated with folic acid-modified pegylated dendrimer | |
| Zhao et al. | High and low molecular weight hyaluronic acid-coated gold nanobipyramids for photothermal therapy | |
| Liu et al. | In situ synthesis of multidentate PEGylated chitosan modified gold nanoparticles with good stability and biocompatibility | |
| Zhai et al. | Nanocellulose: a promising nanomaterial for fabricating fluorescent composites | |
| CN102435571B (en) | Method for detecting heparin content with polyethyleneimine-stabilized gold nanoparticle | |
| CN107661504A (en) | A kind of golden nanometer particle of dendritic macromole modification and its preparation method and application | |
| CN108310397B (en) | Diagnosis and treatment reagent with SERS/fluorescence bimodal targeting tumor cell imaging function and preparation method thereof | |
| Chin et al. | Fluorescein‐labeled starch maleate nanoparticles as sensitive fluorescent sensing probes for metal ions | |
| CN110483683A (en) | A kind of preparation method and purposes of target tumor nano artificial antibody | |
| CN110672567B (en) | Low molecular weight heparin gold nano material and application thereof in heparanase detection | |
| CN113500199B (en) | Preparation method of gold-platinum-based bimetallic active oxygen self-generating nano material, product and application thereof | |
| CN114113028A (en) | Application of Hybrid Crystalline Semiconductor Nanoparticles as Substrates for Surface-Enhanced Laser Raman Spectroscopy | |
| CN115592110A (en) | A gold nanocluster modified by thiol hyaluronic acid and its preparation method | |
| CN110124035A (en) | A kind of gold nanorods/cium carbonate nanoparticles material, preparation method and application | |
| Liu et al. | Cancer specific targeting by glucosamine coated gold nanoparticles in vitro and in vivo | |
| Liu et al. | Preparation and characterization of lectin-conjugated chitosan fluorescent nanoparticles | |
| CN111588690B (en) | A kind of responsive hyaluronic acid fluorescent nanogel, preparation method and application | |
| Gu et al. | An ultrasensitive FRET-based fluorescent low molecular weight heparin nanoprobe for quantifying heparanase activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |